Quantcast
Last updated on April 16, 2014 at 5:14 EDT

Latest Anterior ischemic optic neuropathy Stories

2013-11-19 16:54:03

According to study published in Restorative Neurology and Neuroscience Nonarteritic anterior ischemic optic neuropathy (NAION) is one of the leading causes of sudden and irreversible loss of vision in older adults. In a prospective randomized trial of 60 patients with NAION, investigators have shown that the addition of the corticosteroid fluocortolone (FC) to standard therapy significantly improves both short- and long-term visual acuity, especially when given soon after the onset of...

2012-01-04 07:00:00

FREMONT, Calif., Jan. 4, 2012 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION). QPI-1007 exhibited no dose...

2010-10-20 09:25:00

FREMONT, Calif., Oct. 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection. The Phase I open-label, dose-escalation study was initiated during the...

2010-06-28 07:30:00

FREMONT, Calif., June 28 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal. Prof. Di Polo's recent study in a rat model of glaucoma shows that QPI-1007, when given in two intravitreal...

2010-03-01 08:00:00

FREMONT, Calif., March 1 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007. This drug candidate, having a proprietary siRNA structure, is being developed for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION). The current trial represents the seventh clinical study of Quark...

2007-04-13 09:00:35

pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI), today announced that its subsidiary, AION Diagnostics Inc. will be sold to GEM Global Yield Fund, a portfolio management company. GEM has agreed to pay pSivida US$3 million, payable in two equal installments of US$1.5 million upon the completion of an initial public offering of AION's stock on the Frankfurt Stock Exchange and US$1.5 million payable no later than 12 months after the closing of the transaction, in exchange for pSivida's...

2006-01-16 19:09:39

By Patricia Reaney LONDON (Reuters) - Impotence drugs such as Viagra and Cialis can increase the risk of eye damage in men who have a history of heart disease or high blood pressure, researchers said on Tuesday. In a small study, scientists at the University of Alabama in Birmingham found that men who had suffered a heart attack were 10 times more likely to have optic nerve damage if they had been taking leading anti-impotence pills. "For patients with a history of myocardial...

2005-10-20 15:50:33

By Susan Heavey WASHINGTON (Reuters) - Drugs to treat erectile dysfunction need stronger warnings on their packaging about the risk of blindness, U.S. consumer group Public Citizen said on Thursday in a petition filed with health regulators. The U.S. Food and Drug Administration should "immediately add a black box warning regarding the risks of drug-induced blindness for the three phosphodiesterase 5 (PDE5) inhibitors that are prescribed for the treatment of erectile dysfunction,"...

2005-10-20 10:14:02

By Susan Heavey WASHINGTON (Reuters) - Drugs to treat erectile dysfunction need stronger warnings on their packaging about the risk of blindness, U.S. consumer group Public Citizen said on Thursday in a petition filed with health regulators. The U.S. Food and Drug Administration should "immediately add a black box warning regarding the risks of drug-induced blindness for the three phosphodiesterase 5 (PDE5) inhibitors that are prescribed for the treatment of erectile dysfunction,"...

2005-07-26 15:48:32

TORONTO (Reuters) - Canada advised users of the erectile dysfunction drugs Viagra, Cialis or Levitra on Tuesday to seek "immediate medical attention" if they experience sudden vision loss or other vision problems when taking the drugs. Health Canada, the federal health ministry, also said in a statement it was likely to change the product information for the three popular drugs. Earlier this month the U.S. Food and Drug Administration approved new labeling to warn men about possible...